Shares of NGM Biopharmaceuticals (NGM) are under pressure on Monday after the company said that its Phase 2b trial of aldafermin in non-alcoholic steatohepatitis, or NASH, has missed its primary endpoint. NGM has also… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3309919/-NGM-plunges-after-disappointing-aldafermin-data-in-NASH-study)